Association between NT-proBNP levels and future cardiovascular events in systemic lupus erythematosus: a multicenter longitudinal cohort study
Objective Current strategies for identifying individuals at high risk of cardiovascular events (CVE) in systemic lupus erythematosus (SLE) are lacking. A previous cross-sectional study in SLE showed that NT-proBNP > 133 pg/mL was associated with cardiovascular damage. Our objective was to assess the association between NT-proBNP at a threshold of 133 and incident CVE in SLE. Methods All SLE patients who were included in the randomised controlled trial PLUS between 2007 and 2010 in France were screened. Patients with a history of CVE, an unavailable serum sample at PLUS inclusion, or incomplete follow-up were excluded from the primary analysis. The primary endpoint was the occurrence of CVE during follow-up. Results A total of 351 patients (out of 573 included in PLUS) were analyzed. Of these patients, 316 (90.0%) were women with a median age of 38 [30-48] years. Among them, 24 (6.8%) patients experienced at least one CVE that occurred a median of 5 [3-7] years after baseline. Five patients had more than one CVE. In the multivariable analysis, age, dyslipidemia and NT-proBNP were significantly associated with the occurrence of CVE. NT-proBNP was >133pg/mL in 22 (6.3%) patients at baseline. The 133 pg/ml threshold was significantly associated with the occurrence of CVE during follow-up (adjusted hazard ratio [CI 95]: 2.94; 95% CI: 1.12–7.71). Conclusion A NT-proBNP threshold of 133 pg/ml is associated with future CVE in SLE. SLE care guidelines could consider including NT-proBNP measurement in order to better stratify the cardiovascular prevention strategies in this high-risk population.
Authors
- Alexis Mathian (ORCID: https://orcid.org/0000-0002-7653-6528)
- T. Papo (ORCID: https://orcid.org/0000-0002-7481-5099)
- Anne Boutten (ORCID: https://orcid.org/0000-0002-1293-9096)
- Zahir Amoura (ORCID: https://orcid.org/0000-0003-0292-9043)
- Julie Chezel
- Véronique Le Guern (ORCID: https://orcid.org/0000-0001-6002-8919)
- Cédric Laouenan (ORCID: https://orcid.org/0000-0002-3681-6314)
- Karim Sacré (ORCID: https://orcid.org/0000-0002-6544-234X)
- Sasha Bernatsky (ORCID: https://orcid.org/0000-0002-9515-2802)
- Drifa Belhadi (ORCID: https://orcid.org/0000-0002-0589-6614)
- Arthur Mageau (ORCID: https://orcid.org/0000-0002-2995-767X)
- Nathalie Costedoat-Chalumeau (ORCID: https://orcid.org/0000-0002-1555-9021)
- Nathalie Morel (ORCID: https://orcid.org/0009-0005-2074-7050)
- Évelyne Vinet (ORCID: https://orcid.org/0000-0001-7727-5879)
- Pascale Ghillani‐Dalbin (ORCID: https://orcid.org/0000-0002-1369-7690)
- Kenza Ouacel
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- McGill University Health Centre (CA)
- Sorbonne Université (FR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre de Recherche sur l'Inflammation (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Centre de Recherche Épidémiologie et Statistique (FR)
- Infection, Anti-microbiens, Modélisation, Evolution (FR)
- Université Paris Descartes (FR)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2026-11-15
- DOI
- https://doi.org/10.3899/jrheum.2026-0671
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00